- Home
- DC vs RGNX Comparison
DC vs RGNX Comparison
Compare DC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DC | RGNX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.3M | 661.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | DC | RGNX |
|---|---|---|
| Price | $5.71 | $14.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 1.3M | 626.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $161,318,000.00 |
| Revenue This Year | N/A | $132.80 |
| Revenue Next Year | N/A | $48.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $2.05 | $5.04 |
| 52 Week High | $5.90 | $14.24 |
Technical Indicators
Market Signals| Indicator | DC | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 72.66 | 67.38 |
| Support Level | $5.57 | $12.69 |
| Resistance Level | $5.90 | $13.42 |
| Average True Range (ATR) | 0.29 | 0.84 |
| MACD | 0.11 | 0.13 |
| Stochastic Oscillator | 89.39 | 85.02 |
Price Performance
Historical ComparisonAbout DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine. Company project includes Richmond Hill Project.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.